Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Access Pharmaceuticals Inc. Stories

2011-05-17 07:00:00

DALLAS and NEW YORK, May 17, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes, and RNAi, announced that it had made significant progress with the commercial introduction of MuGard in the radiation oncology and medical oncology communities. MuGard is a novel, ready-to-use mucoadhesive oral wound rinse and coating that has been shown to be...

2011-05-10 07:49:00

DALLAS and NEW YORK, May 10, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that it has made significant progress with its CobaCyte(TM) tumor-targeting technology. Using a new proprietary CobaCyte paclitaxel nanoparticle formulation, named Cobraxane(TM), the company's scientists have observed...

2011-04-27 07:00:00

DALLAS and NEW YORK, April 27, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, diabetes and RNAi, will attend this year's Oncology Nursing Society (ONS) Congress at the Boston Convention and Exhibition Center in Boston, MA. The company's MuGard booth (#652) will be displayed in the Exhibition Hall of the convention center from Thursday, April 28th to...

2011-04-13 07:15:00

DALLAS and NEW YORK, April 13, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major pharmaceutical company to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics. Access will provide the pharmaceutical company with CobOral and...

2011-03-23 07:15:00

DALLAS and NEW YORK, March 23, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has named Anthony Mottola as its Vice President of Managed Care and Market Access. A 16-year industry veteran, Mottola brings to Access an extensive pharmaceutical industry knowledge and experience in specialty pharmacy,...

2011-03-01 07:15:00

DALLAS and NEW YORK, March 1, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, will host a conference call on Wednesday, March 23rd to update investors on its ongoing commercial and development strategy. Management will discuss the progress made within each of Access' programs, including an update on...

2011-02-09 07:00:00

DALLAS and NEW YORK, Feb. 9, 2011 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, reported it has been receiving positive clinical feedback from doctors and nurse practitioners prescribing MuGard for patients undergoing radiation and chemotherapy for various cancers. For example, Access received feedback...

2010-12-10 08:20:00

DALLAS and NEW YORK, Dec. 10, 2010 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has entered into definitive agreements with existing and new accredited investors to sell, in a registered direct offering, an aggregate of approximately 2.3 million shares of its common stock at a price of $2.55 per...

2010-12-09 07:00:00

DALLAS and NEW YORK, Dec. 9, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has made significant progress in obtaining MuGard reimbursements from various third-party payer networks. Some of the national insurance reimbursements included several state plans from Blue Cross Blue Shield,...

2010-12-08 07:00:00

DALLAS and NEW YORK, Dec. 8, 2010 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major global pharmaceutical company to test Access' oral insulin formulation based upon its proprietary vitamin B-12-based CobOral(TM) Drug Delivery Technology. Access will...